Saurabh Chhabra, MD, MS

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine
MS

Biography

Saurabh Chhabra, MD, is assistant professor of medicine at the Medical College of Wisconsin in the Division of Hematology and Oncology. He specializes in the management of multiple myeloma and in Blood and Marrow Transplantation for hematologic malignancies.

He is a graduate of University College of Medical Sciences, University of Delhi, India. He completed his Internal Medicine residency in 2008 and Fellowship in Hematology/Oncology in 2011, at Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ. He then went on to complete a Fellowship in Blood and Marrow Transplantation at Stanford University in Stanford, CA in 2012. Dr. Chhabra was recruited from Stanford to Charleston, SC as an Assistant Professor in Medicine, in the Division of Hematology/Oncology at Medical University of South Carolina where he was a member of the Hematologic Malignancies/BMT program. He directed the Plasma Cell Disorders clinic at MUSC and was the site Principal Investigator of several industry-sponsored and cooperative group clinical trials, including the BMT Clinical Trials Network (CTN) trials. Dr. Chhabra received the coveted “Outstanding Clinician Award” in 2015 for his services at MUSC. He joined the Froedtert & the Medical College of Wisconsin in 2016.

Research Interests

Dr. Chhabra is board-certified in Internal Medicine, Medical Oncology and Hematology. He has authored or co-authored numerous publications, including journal articles, meeting abstracts and four book chapters. His current research interests include treatment of patients with high-risk plasma cell neoplasms and allogeneic hematopoietic cell transplantation.

Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

(Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM.) Bone Marrow Transplant. 2021 Sep;56(9):2319 PMID: 34017072 SCOPUS ID: 2-s2.0-85106222684 05/22/2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

(Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM.) Bone Marrow Transplant. 2021 Sep;56(9):2108-2117 PMID: 33864019 PMCID: PMC8425595 SCOPUS ID: 2-s2.0-85104540946 04/18/2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.

(Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W.) Transplant Cell Ther. 2021 Aug 14 PMID: 34403791 08/18/2021
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy.

(Dhakal B, Abedin SM, Fenske TS, Chhabra S, Ledeboer N, Hari P, Hamadani M.) Blood. 2021 Aug 02 PMID: 34339501 PMCID: PMC8332674 08/03/2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.

(Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M.) Blood. 2021 07 22;138(3):273-282 PMID: 34292325 PMCID: PMC8310426 07/23/2021
Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis.

(Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, Hamadani M, Chhabra S.) Bone Marrow Transplant. 2021 Jul 14 PMID: 34262142 07/16/2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.

(Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A.) Leukemia. 2021 Jul;35(7):2141 PMID: 34091601 SCOPUS ID: 2-s2.0-85107532822 06/07/2021
Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation.

(Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A.) Leuk Res. 2021 Jun 23;109:106648 PMID: 34182226 SCOPUS ID: 2-s2.0-85109506946 06/29/2021
Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

(Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2021 Jun 18 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.

(Wilson WH, Phillips T, Popplewell L, de Vos S, Chhabra S, Kimball AS, Beaupre D, Huang DW, Wright G, Kwei K, Ping J, Neuenburg JK, Staudt LM.) Leuk Lymphoma. 2021 Apr 15:1-13 PMID: 33856277 SCOPUS ID: 2-s2.0-85104450115 04/16/2021
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.

(Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M.) Blood. 2021 Apr 13 PMID: 33851205 SCOPUS ID: 2-s2.0-85111698532 04/15/2021
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

(Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S.) Front Immunol. 2021;12:667054 PMID: 34149703 PMCID: PMC8206561 SCOPUS ID: 2-s2.0-85108140164 06/22/2021